Evaluation of absorbed dose in Gadolinium neutron capture therapy

• Authors: Gayane Abdullaeva , Gulnara Djuraeva , Andrey Kim , Yuriy Koblik , Gairatulla Kulabdullaev , Turdimukhammad Rakhmonov , Shavkat Saytjanov
• Languages of publication: EN

Abstracts

EN

Gadolinium neutron capture therapy (GdNCT) is
used for treatment of radioresistant malignant tumors. The
absorbed dose in GdNCT can be divided into four primary
dose components: thermal neutron, fast neutron, photon
and natural gadolinium doses. The most significant
is the dose created by natural gadolinium. The amount of
gadolinium at the irradiated region is changeable and depends
on the gadolinium delivery agent and on the structure
of the location where the agent is injected. To de-
fine the time dependence of the gadolinium concentration
ρ(t) in the irradiated region the pharmacokinetics of
gadolinium delivery agent (Magnevist) was studied at intratumoral
injection in mice and intramuscular injection
in rats. A polynomial approximation was applied to the experimental
data and the influence of ρ(t) on the relative
change of the absorbed dose of gadolinium was studied.

Keywords

EN

GdNCT; Magnevist; absorbed dose; kerma; amount of gadolinium

• Publisher: De Gruyter Open
• Journal: Open Physics
• Year: 2015
• Volume: 13
• Issue: 1

Dates

accepted

1 - 1 - 2015

received

20 - 6 - 2014

online

27 - 2 - 2015

Contributors

author

Gayane Abdullaeva

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Gulnara Djuraeva

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Andrey Kim

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Yuriy Koblik

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Gairatulla Kulabdullaev

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Turdimukhammad Rakhmonov

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

author

Shavkat Saytjanov

• Institute
  of Nuclear Physics Uz AS, Tashkent, Uzbekistan

References

• [1] H.J. Weinmann, R.C. Brasch, W.R. Press, G.S. Wesbey, Am. J.Roentgenol. 142, 619 (1984)[Crossref]
• [2] M. Magerstadt et al., Magn. Reson. Med. 3, 808 (1986)[Crossref]
• [3] G.De Stasio et al., Cancer Res. 61, 4272 (2001)
• [4] Yu.N. Koblik et al., Med. Phys. (Russia) 51, 31 (2011)
• [5] A.A. Kim et al., IJNESE. 4, 43 (2014)
• [6] G.A. Kulabdullaev et al., Uzb. Phys. J. 15, 127 (2013)
• [7] A-F. Miller, Ch.J. Halkides, A.G. Redfield, Biochemistry 32, 7367(1993)[Crossref]
• [8] J. Stepanek, Excerpta Med. Int. Cong. Series 1132, 425 (1997)
• [9] C.K.C. Wang, M. Sutton, T.M. Evans, B.H. Laster, A microdosimetricstudy of 10B(n,γ)7Li and 157Gd(n,) reactions for neutroncapture therapy, In Proceedings of the Sixth InternationalRadiopharmaceutical Dosimetry Symposium, (Institute for Scienceand Education, Oak Ridge, TN 1999), 336
• [10] T. Goorley, H. Nikjoo, Radiat. Res. 54, 556 (2000)
• [11] M. Rivard, J. Stepanek, Med. Phys. 27, 1544 (2000)
• [12] S.A. Klykov et al., At. Energ. 91, 6 ( 2001)
• [13] Y. Sakurai, T. Kobayashi, J. Nucl. Sci. Technol. S2, 1294 ( 2002)[Crossref]
• [14] I. Sheino, V. Khokhlov, V. Kulakov, K. Zaitsev, In: S. Taskaev(Ed.), Estimation of neutron kerma in biological tissue containingboron and gadolinium compounds for neutron capture therapy,Proceedings Intern. Symposium on Boron Neutron CaptureTherapy, July 7-9, 2004, Novosibirsk, Russia (2004)
• [15] K. Zaitsev et al., In: S. Taskaev (Ed.), NCT at the MEPhI reactor,Proceedings Intern. Symposium on Boron Neutron CaptureTherapy, July 7-9, 2004, Novosibirsk, Russia (2004)
• [16] G.A. Abdullaeva et al., Bull. Rus. Acad. 73, 512 (2009)
• [17] G.A. Abdullaeva et al., Atom. Energy 115, 166 (2013)
• [18] H. Tokumitsu, H. Ichikawa, Y. Fukumori, J. Pharm. Res. 16, 1830(1999)[Crossref]
• [19] B. Hofmann et al., Invest. Radiol. 34, 126 (1999)[Crossref]

Identifiers

DOI

10.1515/phys-2015-0022